四川和谐双马股份有限公司 2024年度独立董事述职报告 （述职人：姚立杰） 一、独立董事的基本情况 姚立杰：女，中国国籍。2009 年清华大学经管学院毕业，获博士学位。2009 年 7 月至 2011 年 11 月在北京交通大学，担任讲师职务，负责教学科研。2011 年 12 月-2018 年 12 月在北京交通大学，担任副教授职务，负责教学科研。2018 年 12 月至今在北京交通大学，担任教授职务。现任北京交通大学经管学院会计 系教授、高质量发展研究院院长，同时兼任朗新科技集团股份有限公司独立董事。 不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会及股东大会的情况 2024 年本人以通讯的方式共出席五次董事会，均亲自出席会议，不存在委 托出席的情况。在审议议案时，本人着重关注公司履行会计信息质量主体责任情 况，要求公司严格按照企业会计准则要求，结合公司业务实质进行会计处理和信 息披露。本人对所审议的议案进行认真审查，对全部议案均表示同意，切实履行 了独立董事职责。报告期内，公司召开了一次股东大会，出于工作原因，本人未 出席股东大会，本人密切关注公司与投资者现场沟通情况，深入考虑投资者建 ...

《董事会议事规则》修改对照表（2025 年 4 月） | 序号 | 《董事会议事规则》（现行） | 《董事会议事规则》（拟修订） | | --- | --- | --- | | | 第三条 本议事规则条款与上述法律、法规 | | | 1 | 和公司章程若有抵触，以法律、法规和公司章程 | 第三条 本议事规则条款与法律、法规和公司章程 | | | 的规定为准。 | 若有抵触，以法律、法规和公司章程的规定为准。 | | | 第五条 董事会行使下列职权： | | | | （一）召集股东大会，并向股东大会报告工 | | | | 作； | | | | | 第五条 董事会行使下列职权： | | | （二）执行股东大会的决议； | （一）召集股东会，并向股东会报告工作； | | | （三）决定公司的经营计划和投资方案； | （二）执行股东会的决议； | | | （四）制订公司的年度财务预算方案、决算 | （三）决定公司的经营计划和投资方案； | | | 方案； | （四）制订公司的利润分配方案和弥补亏损方案； | | | （五）制订公司的利润分配方案和弥补亏损 | | | | 方案； | （五）制订公司增加或者减少注册资本 ...

四川和谐双马股份有限公司 2024年度独立董事述职报告 （述职人：许劲生） 一、独立董事的基本情况 许劲生：男，中国国籍。北京大学毕业，获经济学学士和硕士学位。1990 年 8 月至 1991 年 7 月，北京牧工商总公司，办公室秘书；1991 年 8 月至 2000 年 6 月，中国海外工程总公司，任项目经理，负责分、子公司的管理；2000 年 7 月至 2001 年 6 月，慧聪集团，任新产品开发部副总经理，负责新产品的研究； 2001 年 7 月至 2002 年 9 月，西部证券，任北京管理总部副总经理，负责北京营 业部的筹建；2002 年 9 月至 2006 年 6 月，北京珠峰万维科技有限公司，任副总 经理，负责视频会议的研发运营；2006 年 6 月至 2018 年 11 月，北京中搜网络 技术公司，任内容运营总监，负责内容运营管理；2018 年 12 月至今，独立投资 人。不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会及股东大会的情况 2024 年本人以通讯方式共出席五次董事会，均亲自出席会议，不存在委托 出席的情况。本人结合公司情况，深入分析相关业务的背景材料及行业趋势， ...

《股东会议事规则》修改对照表（2025 年 4 月） | 序号 | 《股东大会规则》（现行） | 《股东会议事规则》（拟修订） | | --- | --- | --- | | 1 | 四川和谐双马股份有限公司股东大会规则 | 四川和谐双马股份有限公司股东会议事规则 | | | | 第二条 公司股东会的召集、提案、通知、召开等事 | | 2 | （新增） | 项适用本议事规则。 | | | 第四条 股东大会分为年度股东大会和临 | 第五条 股东会分为年度股东会和临时股东会。年 | | | 时股东大会。年度股东大会每年召开一次，应当 | | | | | 度股东会每年召开一次，应当于上一会计年度结束后的 | | | 于上一会计年度结束后的 6 个月内举行。临时股 | 六个月内举行。临时股东会不定期召开，出现《公司法》 | | | 东大会不定期召开，出现《公司法》第一百条规 | 第一百一十三条规定的应当召开临时股东会的情形时， | | 3 | 定的应当召开临时股东大会的情形时，临时股东 | 临时股东会应当在两个月内召开。 | | | 大会应当在 2 个月内召开。 | | | | | 公司在上述期限内不能召开股东会的， ...

Financial Performance - The company's revenue for Q1 2025 was ¥324,988,710.21, representing a 52.53% increase compared to ¥213,059,095.23 in the same period last year[5] - Net profit attributable to shareholders reached ¥116,549,153.25, a significant increase of 1,236.09% from ¥8,723,136.67 in the previous year[5] - The basic earnings per share rose to ¥0.15, marking a 1,400.00% increase from ¥0.01 in the same period last year[5] - Total operating revenue for the current period reached ¥324,988,710.21, a significant increase from ¥213,059,095.23 in the previous period, representing a growth of approximately 52.5%[23] - Net profit for the current period was ¥116,217,737.32, compared to ¥8,259,988.85 in the previous period, indicating a substantial increase of approximately 1,307.5%[24] - Total comprehensive income amounted to CNY 116,220,312.46, a significant increase from CNY 8,281,557.48 in the previous period[25] - Basic and diluted earnings per share both increased to CNY 0.15 from CNY 0.01[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥9,030,246,383.08, a 0.43% increase from ¥8,991,376,516.63 at the end of the previous year[5] - The company's total assets amounted to ¥9,030,246,383.08, up from ¥8,991,376,516.63, reflecting a growth of about 0.4%[22] - Total liabilities decreased to ¥1,360,958,888.76 from ¥1,438,309,334.74, showing a reduction of approximately 5.4%[22] - The company's total liabilities decreased by 58.19% in other payables, amounting to ¥38,241,994.79, primarily due to dividend payments to shareholders[10] - The company's equity attributable to shareholders increased to ¥7,591,869,474.09 from ¥7,475,317,745.70, representing a growth of about 1.6%[22] Cash Flow - The company reported a net cash flow from operating activities of ¥38,529,015.68, which is a decrease of 26.71% compared to ¥52,573,281.08 in the same period last year[5] - Cash inflow from operating activities reached CNY 352,461,745.55, compared to CNY 189,337,069.31 in the prior period, reflecting an increase of approximately 86.2%[25] - Net cash flow from operating activities was CNY 38,529,015.68, down from CNY 52,573,281.08, indicating a decrease of about 26.7%[25] - Cash outflow for investing activities totaled CNY 19,758,234.35, significantly lower than CNY 710,797,749.80 in the previous period[26] - Net cash flow from investing activities was CNY 1,074,123.67, a recovery from a negative cash flow of CNY -125,260,564.83 in the prior period[26] - The company reported a net increase in cash and cash equivalents of CNY 33,739,556.42, contrasting with a decrease of CNY -75,045,017.00 in the prior period[26] Shareholder Structure - The largest shareholder, Beijing Harmony Hengyuan Technology Co., Ltd., holds 26.52% of shares, totaling 202,446,032 shares, with 124,005,100 shares pledged[17] - The second largest shareholder, LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD., owns 17.55% of shares, amounting to 133,952,761 shares[17] - Tianjin Saike Environmental Management Center (Limited Partnership) holds 10.24% of shares, which is 78,203,902 shares[17] - CITIC Financial Asset Management Co., Ltd. possesses 7.45% of shares, equating to 56,854,045 shares[17] - Zhongrong Life Insurance Co., Ltd. holds 6.80% of shares, totaling 51,919,170 shares[17] - The Basic Pension Insurance Fund No. 1003 holds 1.23% of shares, which is 9,414,734 shares[17] - The top ten shareholders collectively represent a significant portion of the company's equity, with the largest three shareholders alone accounting for over 54%[17] - The shareholder structure indicates a concentration of ownership, which may impact governance and strategic decisions[17] Research and Development - Research and development expenses increased to ¥14,741,288.49, reflecting a 100.00% increase as a result of the acquisition of Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.[13] - Research and development expenses for the current period were ¥14,741,288.49, compared to ¥0.00 in the previous period, indicating a new investment in innovation[23] Fair Value and Investment Income - The company reported a significant increase in fair value gains of ¥82,252,243.83, compared to a loss of ¥66,419,972.85 in the previous year[13] - The company’s investment income showed a loss of ¥23,203,645.78, an improvement from a loss of ¥31,795,847.80 in the previous year[13] Future Outlook - Future outlook includes plans for market expansion and potential new product launches, aiming to sustain growth momentum[23] Other Information - The company did not undergo an audit for the first quarter report[27] - The company is set to implement new accounting standards starting from 2025[28]

Financial Performance - The company’s operating revenue for 2024 was CNY 1,074,557,678.81, a decrease of 11.87% compared to CNY 1,219,344,574.84 in 2023[19]. - Net profit attributable to shareholders for 2024 was CNY 309,381,386.88, down 68.61% from CNY 985,473,578.62 in 2023[19]. - The net profit after deducting non-recurring gains and losses was CNY 60,529,601.91, a decline of 93.55% from CNY 938,711,142.26 in 2023[19]. - Cash flow from operating activities increased by 49.68% to CNY 462,917,152.00 in 2024, compared to CNY 309,272,676.46 in 2023[19]. - Basic earnings per share for 2024 were CNY 0.41, a decrease of 68.22% from CNY 1.29 in 2023[19]. - Total assets at the end of 2024 were CNY 8,991,376,516.63, reflecting a 9.72% increase from CNY 8,194,608,917.06 at the end of 2023[19]. - The weighted average return on equity decreased by 9.93 percentage points to 4.17% in 2024 from 14.10% in 2023[19]. - The company reported a significant decline in net profit, with the lowest of total profit, net profit, and net profit after deducting non-recurring gains and losses being negative for the most recent accounting year[20]. Business Operations and Strategy - The company has undergone changes in its main business operations, shifting from cement manufacturing to include building materials, biopharmaceuticals, and private equity fund management[18]. - The company aims to enhance its core capabilities through organic growth and external investments, focusing on high-growth areas such as biotechnology[33]. - The company is committed to sustainable development and aims to achieve dual carbon goals, aligning with national policies on green development[33]. - The company is actively implementing a carbon reduction plan and researching new cement technology to achieve high-quality development[38]. - The company has established a solid foundation for future drug supply by collaborating deeply with innovative pharmaceutical companies from the product development stage[67]. Market Conditions - In 2024, China's cement production reached 1.825 billion tons, a year-on-year decrease of 9.5%, marking the lowest output since 2010[34]. - National real estate development investment fell by 10.6% year-on-year, with new housing starts declining by 23.0%[34]. - The company maintained a leading market share in the regional market, benefiting from strong brand recognition and stable partnerships with major projects[41]. - The company's aggregate business faced price declines throughout the year, but experienced a recovery towards the end due to environmental regulations and increased self-discipline among leading enterprises[35]. - The cement and aggregate market demand in the company's production area remained weak in 2024, with product sales prices significantly declining compared to the same period last year[80]. Research and Development - The company has established a comprehensive R&D system with over 210 personnel, focusing on advanced chemical synthesis processes for peptide drugs[71]. - The company has over 20 ongoing peptide research projects, with significant progress in global registration, including multiple DMF filings in the US and Korea[93]. - The company has received FDA First Adequate Letter for its acetate degarelix raw material, indicating compliance with US regulatory standards[66]. - The company has developed a peptide separation and purification platform that integrates various advanced chromatography technologies, significantly enhancing the efficiency of peptide production[112]. - The company has invested nearly 100 million yuan in a state-of-the-art R&D laboratory exceeding 7,000 square meters, equipped with advanced instruments ensuring research accuracy[114]. Investment and Financial Management - The company generated investment income of 1.545 billion yuan from two funds, with an expected additional performance fee of 1.023 billion yuan upon full exit at fair value[87]. - The company has established a strong compliance framework to ensure efficient fund operations and protect investor interests[103]. - The company is committed to supporting the real economy and contributing to high-quality economic development through its investment strategies[104]. - The company has a robust operational process and a high-efficiency team collaboration mechanism, ensuring scientific and effective decision-making[100]. - The company plans to leverage capital market tools to support the development of strategic emerging industries, including biotechnology and artificial intelligence[172]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report, taking legal responsibility for its content[4]. - The report indicates that all board members attended the meeting to review the annual report, ensuring collective accountability[4]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its strategic outlook[4]. - The company has made provisions for future disclosures and updates through its official channels, ensuring transparency for investors[9]. - The company’s governance structure includes a board of directors and supervisory board, ensuring effective decision-making and oversight for long-term stability[33]. Environmental and Social Responsibility - The company has been recognized as a provincial-level safety culture construction demonstration enterprise, emphasizing its commitment to employee health and safety[108]. - The company has received multiple awards for product quality in its building materials manufacturing business, enhancing its brand reputation[106]. - The company has implemented the SCR ultra-low emission project, significantly reducing nitrogen oxide emissions[108]. - The company has been recognized as a provincial-level environmental integrity enterprise for four consecutive years, demonstrating its commitment to ecological protection[108]. - The company is focused on expanding its product and customer structure, aiming for breakthroughs in market regions despite a challenging economic environment[61].

Financial Performance - Total revenue for 2024 was CNY 107,455.77 million, a decrease of 11.87% compared to CNY 121,934.46 million in the previous year[3] - Operating profit fell to CNY 29,182.95 million, down 74.32% from CNY 113,621.30 million year-on-year[3] - Net profit attributable to shareholders decreased by 68.61% to CNY 30,938.14 million from CNY 98,547.36 million in the previous year[3] - The basic earnings per share dropped to CNY 0.41, a decline of 68.22% compared to CNY 1.29 in the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 6,052.96 million, a significant drop of 93.55% from CNY 93,871.11 million year-on-year[3] - The weighted average return on equity decreased to 4.17%, down 9.93 percentage points from 14.10% in the previous year[3] Operational Challenges - The company faced challenges due to capital market fluctuations and slow recovery in market demand for building materials, impacting overall sales volume and prices[5] - The company is actively optimizing operational efficiency and controlling costs to mitigate the impact of declining performance[5] Strategic Initiatives - A strategic acquisition of Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. was made to establish a solid foundation for future growth[5] Asset Management - Total assets increased by 9.72% to CNY 899,137.65 million from CNY 819,460.89 million at the beginning of the period[3]

Financial Performance - The company expects a net profit attributable to shareholders of 100 million to 140 million CNY, representing a growth of 1,047% to 1,506% compared to the same period last year, where the profit was 8.72 million CNY[3] - The net profit after deducting non-recurring gains and losses is projected to be 95 million to 135 million CNY, compared to a loss of 4.21 million CNY in the previous year[3] - Basic earnings per share are estimated to be between 0.13 CNY and 0.18 CNY, up from 0.01 CNY in the same period last year[3] - The significant increase in performance is primarily attributed to good returns from the funds invested by the company during the reporting period[5] Strategic Focus - The company is focusing on cost reduction and efficiency improvement while increasing investment in technological innovation and market expansion[6] - The company aims to lay a solid foundation for stable and healthy future development through its current strategies[6] Earnings Forecast - The earnings forecast is based on preliminary calculations and has not been audited by registered accountants[4] Share Capital - The total share capital as of March 31, 2025, is 763,440,333 shares, with 6,219,875 shares in the repurchase special securities account[3] Information Disclosure - The company emphasizes the importance of timely information disclosure and advises investors to make cautious decisions due to potential risks[7] - The detailed financial data will be disclosed in the first quarter report of 2025[7]

证券代码：000935 证券简称：四川双马 公告编号：2025-9 四川和谐双马股份有限公司 关于控股股东所持部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司(简称"公司"）于近日接到控股股东北京和谐 恒源科技有限公司（简称"和谐恒源"）的告知函，获悉和谐恒源对所持有的本 公司的部分股份办理了质押展期业务，具体事项如下： 上述"占其所持股份比例"为该笔质押股份的数量占和谐恒源及其一致行动 人持股数量的比例。所质押的股份未负担重大资产重组等业绩补偿义务。 上述股份的原质押情况详见公司于2024年4月24日及2024年4月26日披露的 《关于控股股东所持部分股份解除质押及再质押的公告》和《关于控股股东所持 部分股份解除质押及再质押的公告》。依据和谐恒源出具的告知函，和谐恒源对 所持有的本公司的部分股份办理质押展期的主要原因为偿还债务，就质押事项和 谐恒源具备履约偿债能力，所质押的股份不存在平仓风险，对上市公司的生产经 营及公司治理等不会产生影响，和谐恒源已采取相关防范应对措施。 二、股东股份累计被质押的情况 股 东 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-8 四川和谐双马股份有限公司 关于公司董事、副总经理兼董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（以下简称"公司"）董事会于 2025 年 3 月 31 日收到公司董事、副总经理兼董事会秘书陈长春先生提交的书面辞职报告，陈长 春先生由于个人原因提请辞去公司董事、副总经理兼董事会秘书的职务，辞职后 不再担任公司及控股子公司的其他职务。 陈长春先生的辞职不会导致公司董事会成员人数低于法定最低人数，不会影 响公司董事会的正常运作及公司经营管理的正常运行。根据《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，陈长春先 生的辞职报告自送达公司董事会之日起生效。截至本公告披露日，陈长春先生未 持有公司股份，不存在应当履行而未履行的承诺事项。 通讯地址：四川省成都市锦江区红星路三段一号成都国际金融中心 1 号写 字楼 26 楼 2 号 电子邮箱：public.sm@sc-shuangma.com 特此公告。 四川和谐双马股份 ...